H
Harry W. Flynn
Researcher at University of Miami
Publications - 739
Citations - 29677
Harry W. Flynn is an academic researcher from University of Miami. The author has contributed to research in topics: Endophthalmitis & Visual acuity. The author has an hindex of 83, co-authored 709 publications receiving 26642 citations. Previous affiliations of Harry W. Flynn include Bascom Palmer Eye Institute & Cornell University.
Papers
More filters
Journal ArticleDOI
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Anne E. Fung,Geeta A. Lalwani,Philip J. Rosenfeld,Sander R. Dubovy,Stephan Michels,William J. Feuer,Carmen A. Puliafito,Janet L. Davis,Harry W. Flynn,Maria Esquiabro +9 more
TL;DR: In this paper, an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with age-related macular degeneration (AMD) was evaluated.
Journal ArticleDOI
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Geeta A. Lalwani,Philip J. Rosenfeld,Anne E. Fung,Sander R. Dubovy,Stephen Michels,William J. Feuer,Janet L. Davis,Harry W. Flynn,Maria Esquiabro +8 more
TL;DR: The PrONTO Study using an OCT-guided variable-dosing regimen with intravitreal ranibizumab resulted in VA outcomes comparable with the outcomes from the phase III clinical studies, but fewer intravItreal injections were required.
Journal ArticleDOI
Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery
TL;DR: The authors reviewed the incidence of hospital-linked postoperative endophthalmitis at the Bascom Palmer Eye Institute between January 1, 1984 and June 30, 1989 and observed an incidence of 0.093% in cases operated on between September 1, 1976 and December 31, 1982.
Journal ArticleDOI
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Ryan M. Rich,Philip J. Rosenfeld,Carmen A. Puliafito,Sander R. Dubovy,Janet L. Davis,Harry W. Flynn,Serafin Gonzalez,William J. Feuer,Richard C. Lin,Geeta A. Lalwani,Jackie K. Nguyen,Gaurav Kumar +11 more
TL;DR: Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements.
Journal ArticleDOI
Nosocomial acute-onset postoperative endophthalmitis survey: A 10-year review of incidence and outcomes
TL;DR: The visual acuity outcomes were worse in the patients who developed endophthalmitis after PPV than after cataract extraction, glaucoma procedures, or secondary IOL implantation, and these results may serve as a source of comparison for other centers and future studies.